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Abstract
Background Patients requiring an intra-aortic balloon
pump (IABP) after cardiac surgery are critically ill and
need a prolonged ICU stay. Considering limited health care
resources, the early identification of patients with an
extremely poor prognosis is important as a solid base for
the decision whether further aggressive continuation or
cessation of the therapy is recommendable.
Methods From 2001 to 2007, 552 patients with low-output
syndrome after open-heart surgery and IABP implantation
in OR or within 24 h thereafter on ICU were retrospec-
tively analyzed.
Results The overall mortality at 30 and 180-day were 31
and 40 %, respectively. According to multivariate analy-
ses, following factors were used to generate an IABP score:
female gender, age C70 years, simultaneous coronary and
valve surgery, aortic cross-clamp time[120 min., need of
norepinephrin more than 0.4 lg kg-1 min-1, postoperative
dialysis, and maximal serum creatinine kinase
[3000 mg mL-1. The 30-day mortality continuously
increased along the score (10.1 % for score = 0, n = 98;
11.8 % for score = 1, n = 144; 27.5 % for score = 2, n =
153; 40.4 % score = 3, n = 89; 65.2 % for score = 4,
n = 46; 77.8 % for score = 5, n = 27) and reached 100 %
for all patients with a score of 6 (n = 4).
Conclusions Prediction of 30 days mortality was possible
with our scoring system based on multivariate analysis, and
patients with scores of 4 or greater had remarkably worse
early and late survival.
Keywords Cardiac surgery  Low output syndrome 
Intraaortic balloon pumping
Introduction
Intraaortic balloon pumping (IABP) is now the most
commonly used mechanical assist device for postcar-
diotomy low output syndrome (LOS) [1]. There have been
some efforts in the past to predict the prognosis in this
patient cohort [2–6], including the introduction of scoring
systems reported from two German large volume centers,
the German Heart Center Berlin group [4] and Bad
Oeyenhausen group [5]. The aim of previous efforts was
focused on the identification of patients who would benefit
from further aggressive therapy, e.g. with the implantation
of an extracorporeal membrane oxygenation (ECMO) or a
ventricle assist device (VAD). Therefore, those reports
only considered acute parameters (serum lactate level,
hemodynamics, mixed venous saturation, and adrenaline
dose) obtained 1–6 h after surgery. In contrast, preopera-
tive patient characteristics, intraoperative parameters and
postoperative complications were not analyzed by those
reports [4, 5].
However, it is sometimes very difficult to meet a deci-
sion for further therapy escalation immediately after
surgery. For example, there are some patients with post-
cardiotomy LOS, who may initially be stabilized under
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IABP support and moderate inotropic doses, but who will
remain at a remarkably high rate for renal failure, pneu-
monia or other complications, all rapidly leading to multi-
organ failure. Moreover, even after successful early post-
operative recovery and discharge from intensive and
intermediate care unit the mid term results of these patients
remain remarkably limited. For these patients, an alterna-
tive scoring system allowing the prediction of outcomes
which can be applied not only to the very early postoper-
ative period, but also to the postoperative course, may be
helpful to identify patients who need further therapy
escalation to maintain their midterm prognosis.
In recent years, the general cardiac surgical patient
population has shifted towards an older cohort with
increased complexity, and there are many patients in whom
ECMO or VAD are absolutely, relatively or socially con-
traindicated. Previous reports were aimed only for further
escalation of therapy to a point of ECMO or a VAD
implantation. However, our health care resources have
increasingly become under the pressure of financial limi-
tations, excluding the strategy of general implantation of
such devices in all patients in whom an IABP-support is
not enough. An alternative scoring system taking patient
characteristics, intraoperative parameter and postoperative
complication into account may be also helpful to make a
decision to therapy cessation, especially in a prolonged
postoperative course.
The aims of this study were to clarify risk factors for and
to establish a scoring system to predict early and long-term
outcome in patients needing an IABP-support after cardiac
surgery.
Patients and methods
Between November 2001 and December 2007, 9243
patients underwent cardiac surgery and 649 patients
(7.0 %) received an IABP due to perioperative cardiac
low output syndrome (LOS) in our institute. Patient
demographics, preoperative data, intraoperative proce-
dures and postoperative data for the in-hospital course
and the 180-day outcome were prospectively entered in
an institutional data base. A retrospectively evaluation
was performed for all 649 patients, additionally including
a follow-up for the clinical outcome up to the time of the
study. Of all patients, the use of IABP was started pre-
operatively in 47 patients, intraoperatively in 513
patients, postoperatively within the first 24 h in 39
patients, and in further 50 patients after the initial 24
postoperative hours. To focus on postcardiotomy LOS,
patients who received an IABP preoperatively and late
postoperatively after 24 h were excluded from further
analysis. From the remaining 553 patients, one patient
was excluded from further analysis because of lack of
medical records. Thus, 552 patients (512 patients intra-
operative IABP and 39 patients postoperative IABP
within 24 h from the operation) were included in the
analysis. All patients were operated on through the
median sternotomy and cardioplegic cardiac arrest with
Bretschneider-solution.
The indications for IABP implantation included the
following: left atrial pressure or pulmonary artery wedge
pressure increased by[18 mmHg, cardiac index decreased
to\2 L min-1 m-2, and mean systolic arterial pressure
\80 mmHg despite epinephrine support
([0.15 lg kg-1 min-1) for weaning form cardiopul-
monary bypass intraoperatively or for new onset of post-
operative low output syndrome. During IABP therapy,
epinephrine was administrated as inotropic agent and
norepinephrine was administrated for vasoconstriction. The
indications for stopping IABP therapy included the fol-
lowing: stable hemodynamic with minimal epinephrine
support (\0.05 lg kg-1 min-1) and no hemodynamic
deterioration by reduction test of IABP to 1:3 modus. All
patients received heparin infusion on the ICU with the
partial thromboplastin time of 45–50 s.
For data acquisition, the documentation system of the
Heidelberger Verein fu¨r multizentrische Datenanalyse e. V.
(HVMD) was used, where about 1500 variables per case
are entered in prospective manner according to their clin-
ical course [7]. In this system, pulmonary hypertension was
defined as mean pulmonary artery pressure more than
30 mmHg. Short-term mortality up to 180 days was also
documented in HVMD-system. After approval of the
institutional review board, follow-up was obtained through
contact with local population administration office, home
doctor, or with the patient/family directly. Completeness of
follow-up was 97 %.
Statistical analysis
Results are expressed as mean ± standard deviation. Sta-
tistical analysis was performed using Student’s t-test for
continuous variables or v2 tests (Fisher’s exact tests if
n\ 5) for categorical variables. Kaplan–Meier analysis
was used to estimate late mortality between subjected
groups. Logistic regression was also used for the multi-
variate analysis of risk factors for mortality. Receiver
operating characteristics (ROC) curves were used to test
discrimination power of our scoring system. A p value less
than 0.05 was considered significant. All statistical analy-
ses were performed using SPSS 16.0 software (SPSS Inc.,
Chicago, IL).
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Results
Patient demographics and early outcome
Patient characteristics and intraoperative parameters are
listed in Table 1. Early outcome including 30-day mortal-
ity and postoperative complications are listed in Table 2.
The 30-day mortality was 30.8 % in the entire patient
cohort. No patient received a ventricular assist device. Five
patients received an extracorporeal membrane oxygenation
and all of them died.
Univariate and multivariate analyses for 30-day
mortality
All the variables listed in Tables 1 and 2 were analyzed and
following factors listed in Table 3 were identified as risk
factors for 30-day mortality: gender, current smoker, age
above 70 years, the combination of coronary artery bypass
grafting and valve surgery, heart transplantation, operation
time above 300 min, cardiopulmonary bypass time above
180 min, aortic X-clamp time above 120 min, use of
hypothermic circulatory arrest, need of norepinephrine
more than 0.4 lg kg-1 min-1, need of epinephrin more
than 0.2 lg kg-1 min-1, re-thoracotomy due to bleeding,
need for hemodialysis, stroke or prolonged neurological
deficit, laparotomy, sepsis, mechanical ventilation
exceeding 6 days and maximal creatinkinase above 3000
U/L. A multivariate analysis among those factors was
performed and following factors as listed in Table 3 were
identified as independent risk factors: gender, age above
70 years, the combination of coronary artery bypass
grafting and valve surgery, aortic X-clamp time above
120 min, use of hypothermic circulatory arrest, need of
norepinephrine more than 0.4 lg kg-1 min-1, need for
hemodialysis and maximal creatinkinase above
3000 U L-1.
Establishment of a scoring system
According to the result of the multivariate analysis, one
scoring point was given for each independent risk factor;
female (OR 2.211), age above 70 years (OR 1.739), the
combination of coronary artery bypass grafting and valve
surgery (OR 3.793), aortic X-clamp time above 120 min
(OR 2.817), use of hypothermic circulatory arrest (OR
5.101), need of norepinephrine more than 0.4 lg kg-1 -
min-1 (OR 1.881), need for hemodialysis (OR 5.970) and
maximal creatinkinase above 3000 U L-1 (OR 1.714). A
summation of added points was calculated as the actual
score. The distribution of patients and the observed 30-day
mortality dependent on the score is shown in Fig. 1. The
30 days mortality was 10.1 % in patients with 0 point,
11.8 % in patients with 1 point, 27.5 % in patients with 2
points, 40.4 % in patients with 3 points, 65.2 % in patients
with 4 points, 77.8 % in patients with points 5 and 100 %
in patients with points 6. Discrimination by ROC analysis
was 0.76 (0.71–0.80, Fig. 2).
Long-term survival according to the scoring system
Survival curve in the entire patient cohort is shown in
Fig. 3a. Overall cumulative survivals were 69.2 % after
30 days, 59.3 % after 180 days, 56.6 % after 1 year and
46.8 % after 5 years. Survival curve according to the
scoring system is shown in Fig. 3b. Patients with 4 or more
points had extreme poor long-term survival.
Discussion
The crucial findings of the present study were: (1) signif-
icant risk factors could be identified in a relatively large
patient cohort needing IABP after cardiac surgery, (2) the
prediction of 30-day mortality was possible with our
scoring system based on a multivariate analysis, and (3)
long-term survival was extremely poor in patients with
high score values.
In the present study, gender, age above 70 years, com-
bined coronary and valve surgery, aortic X-clamp time
above 120 min, use of hypothermic circulatory arrest, need
of norepinephrine more than 0.4 lg kg-1 min-1, need for
hemodialysis and maximal creatinkinase levels above
3000 U L-1 were independent risk factors for early mor-
tality. Interpreting our findings, female and elderly patients,
patients undergoing extensive surgery and displaying
postoperative vasoplegia, perioperative myocardial infarc-
tion or postoperative renal failure were at particularly
elevated risk for early mortality. These findings per se may
not be surprising because all of these factors are already
well known risk factors in cardiac surgery, independent of
a need for IABP-support [8–10]. Nevertheless, our findings
would be worth, on the one hand to confirm those risk
factors in a large patient cohort, on the other hand to extend
their focused validation to a cohort of critically ill patients
needing IABP-support due to LOS after cardiac surgery.
With our new scoring system, a prediction of 30 days
mortality was possible. Efforts to establish a scoring sys-
tem designed for patients with an IABP-support due to
LOS after cardiac surgery have already been made by
others to know who would need a further therapy escala-
tion with an ECMO or a VAD, as already depicted in the
introduction. We consider that scoring systems based on
early postoperative hemodynamic parameters as reported
by two German large volume centers, the German Heart






Male (%) 372 (67.4 %)
Age (years) 66.7 ± 12.0
Body mass index (kg m-2) 27.0 ± 4.0
Diabetes mellitus (%) 96 (17.4 %)
Hyperlipidemia (%) 424 (76.8 %)
Hypertension (%) 481 (87.1 %)
Current smoker (%) 98 (17.8 %)
Pulmonary hypertension (%) 152 (27.5 %)
Peripheral artery disease (%) 104 (18.8 %)
COPD (%) 185 (33.5 %)
Renal insufficiency (%) 176 (31.9 %)
Renal insufficiency on dialysis (%) 15 (2.7 %)
Serum creatinine (mg/dL) 1.2 ± 0.8
Lever cirrhosis (%) 14 (2.5 %)
Poor LV function (%) 202 (36.6 %)
Emergency (%) 370 (67.0 %)
Re-do operation (%) 17 (5.3 %)
NYHA class IV, n (%) 309 (56.0 %)
Re-do, n (%) 77 (14.1 %)
Operation
CABG 319 (57.8 %)
Valve 69 (12.5 %)
Aortic valve replacement 15 (21.7 %)
Mitral valve replacement 12 (17.4 %)
Mitral valve repair 6 (8.7 %)
Aortic and mitral valve replacement 10 (14.5 %)
Aortic valve replacement and mitral valve repair 4 (5.8 %)
Mitral valve replacement and tricuspid valve repair 5 (7.2 %)
Mitral valve repair and tricuspid valve repair 3 (4.3 %)
Aortic and mitral valve replacement and tricuspid valve repair 12 (17.4 %)
Aortic valve replacement and mitral and tricuspid valve repair 2 (2.9 %)
CABG ? valve 118 (21.4 %)
Aortic valve replacement 45 (38.1 %)
Mitral valve replacement 12 (10.2 %)
Mitral valve repair 8 (6.8 %)
Aortic and mitral valve replacement 10 (8.5 %)
Aortic valve replacement and mitral valve repair 6 (5.1 %)
Mitral valve replacement and tricuspid valve repair 7 (5.9 %)
Mitral valve repair and tricuspid valve repair 6 (5.1 %)
Aortic and mitral valve replacement and tricuspid valve repair 15 (12.7 %)
Aortic valve replacement and mitral and tricuspid valve repair 3 (2.5 %)
HTx 22 (4.0 %)
Surgery on aortic arch 11 (2.0 %)
Miscellaneous 13 (2.1 %)
Intraoperative parameters
Operation time (min) 308 ± 122
Cardiopulmonary bypass time (min) 161 ± 78
X-Clamp time (min) 71 ± 38
Gen Thorac Cardiovasc Surg (2016) 64:584–591 587
123
Center Berlin Group [4] and Bad Oeyenhausen Group [5],
are particularly reliable scoring systems to detect such
patients. One remarkable disadvantage of these two scoring
systems is; however, that they are not designed to be
applied on patients who are initially stable on a marginal
level with an IABP-support and moderate or high dose of
inotropic support. Notably, a prediction of the outcome in
the course of postoperative ICU-stay, as it may become
possible with our new scoring system, appears of signifi-
cant clinical relevance.
To our best knowledge, there has been only one study
reported by Arafa OE et al. in the year 1998 on long-term
survival in patients needing an IABP-support due to LOS
after cardiac surgery [2]. The authors analyzed long-term
survival of 344 patients undergoing cardiac operations who
required the perioperative use of an IABP from 1980 to
1989, and the survival rates were 40 % after 1 year and
32 % after 5 years. In contrast to their study, the survival
rates in the present study were 57 % after 1 year and 47 %
after 5 years, which partly may be explained by the
advancement of cardiac surgical techniques and the
intensive care therapy from the 1980’s to 2000’s. Never-
theless, our results suggest that patients needing an IABP-
support due to LOS after cardiac surgery still belong to a
high risk cohort. This becomes obvious in an almost dra-
matic way, when patients with scores 4 or more and their
outcome are analyzed in the present study. From this
aspect, a further therapy escalation with an ECMO or a
VAD should be reconsidered, particularly in patients with
high score values, where careful selection deserves great
attention of therapy guiding medical team.
As already suggested by the previous two reports on
IABP scores [4, 5], all patients in whom an IABP-support
is not enough to maintain appropriate circulation could
theoretically be considered as candidates for a further
therapy escalation with an ECMO or a VAD. However, one
should be aware that an ECMO and a VAD are no magical
devices capable of saving all patients suffering from a post-
cardiotomy cardiogenic shock. The Leipzig group reported
in the year 2010 on 517 patients treated with an ECMO for
refractory postcardiotomy cardiogenic shock [11]. In their
report, weaning from ECMO was successful in 63 % of the
patients and 25 % could be discharged. Cumulative sur-
vivals were 18 % after 6 months, 17 % after 1 year and
14 % after 5 years [11]. In contrary, the results for patients
receiving a VAD appear to be more encouraging [12]. A
study based on the data from the Society of Thoracic
Surgeon’s National Cardiac Database, early mortality after
VAD-implantation in patients with postcardiotomy shock
has dramatically decreased over time, reaching mortality a
rate of only 41 % between 2002 and 2004 [13]. However,
almost half of these patients received a VAD for weaning
from cardiopulmonary bypass and about 40 % of all
operations were performed on an elective base in this
study. Therefore, it may be possible that a large percentage
of the involved cases were performed with a VAD stand-
by, which may have led to those excellent results [13].
Undoubtedly, there are many patients with postcar-
diotomy cardiogenic shock in whom an IABP-support is
not enough, as revealed by the high 30-day mortality in the
present study reaching 31 %. For such patients, further
therapy escalation with an ECMO or a VAD is the last
hope. However, not all the patients could be saved with an
ECMO and a VAD, and therefore patient selection is of
paramount importance, not only because of medical rea-
sons, but also because of limited health care resources.
Moreover, there also exist many patients in whom further
therapy escalation is actually contraindicated and yet they
cannot be weaned from IABP while ICU-stay prolongs, in
some cases reaching 10 days or more. In such a situation,
Table 2 Postoperative
mortality and complications
30-day mortality 170 (30.8 %)
30-day mortality in patients receiving IABP intraoperatively 159/512 (31.1 %)
30-day mortality in patients receiving IABP postoperatively 11/39 (28.2 %)
Duration of IABP-support (days) 5.6 ± 4.9
Ventilation time (days) 6.0 ± 10.4
ICU-stay (days) 9.5 ± 12.8
Norepinephrine[0.4 lg kg-1 min-1 134 (24.2 %)
Epinephrine[0.2 lg kg-1 min-1 397 (71.9 %)
Max. creatine kinase (mg mL-1) 2144 ± 3177
Max. CK-MB (mg mL-1) 141 ± 152
Hemodialysis 175 (31.7 %)
Rethoracotomy due to bleeding 58 (10.7 %)
Stroke or prolonged neurological deficit 55 (10.0 %)
Sepsis 76 (13.8 %)
Laparotomy 43 (7.8 %)
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Table 3 Univariate and
Multivariate analyses for 30-day
mortality
Mortality Univariate analysis Multivariate analysis
p p OR 95 % CI
Gender
Male 90/372 (24.2 %) 0.0001 0.001 2.211 1.359 3.598
Female 80/180 (44.4 %)
Current smoker
Yes 19/98 (19.4 %) 0.007 0.404 0.746 0.374 1.486
No 151/454 (33.3 %)
Age[70 years
Yes 107/266 (40.2 %) 0.0001 0.029 1.739 1.059 2.856
No 63/286 (24.2 %)
CABG ? valve
Yes 56/118 (47.5 %) 0.0001 0.001 3.793 1.734 8.295
No 114/444 (26.3 %)
Heart transplantation
Yes 2/22 (9.1 %) 0.024 0.053 0.185 0.034 1.021
No 168/530 (31.7 %)
Operation time[300 min
Yes 96/247 (38.9 %) 0.0001 0.628 1.170 0.620 2.206
No 74/305 (24.3 %)
CPB time[180 min
Yes 73/173 (42.2 %) 0.0001 0.523 1.260 0.619 2.565
No 92/371 (44.4 %)
Aortic X-clamp time[120 min
Yes 24/46 (52.2 %) 0.001 0.021 2.817 1.171 6.776
No 141/497 (28.4 %)
Use of hypothermic circulatory arrest
Yes 18/30 (60.0 %) 0.0001 0.002 5.101 1.786 14.571
No 147/513 (28.7 %)
Norepinephrine[0.4 lg kg-1 min-1
Yes 56/134 (41.8 %) 0.0001 0.016 1.881 1.124 3.146
No 106/410 (25.9 %)
Epinephrine[ 0.2 lg kg-1 min-1
Yes 130/397 (32.7 %) 0.013 0.370 1.283 0.744 2.215
No 32/147 (21.8 %)
Rethoracotomy due to bleeding
Yes 25/58 (43.1 %) 0.032 0.190 1.588 0.796 3.169
No 145/494 (29.4 %)
Postoperative hemodialysis
Yes 99/175 (56.6 %) 0.0001 0.0001 5.970 3.414 10.441
No 71/377 (18.8 %)
Stroke or prolonged neurological deficit
Yes 24/55 (43.6 %) 0.030 0.067 1.973 0.953 4.082
No 146/497 (29.4 %)
Laparotomy
Yes 22/43 (51.2 %) 0.003 0.553 1.282 0.564 2.913
No 148/499 (29.1 %)
Sepsis
Yes 38/76 (50.0 %) 0.0001 0.981 1.009 0.482 2.111
No 132/476 (27.7 %)
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the physician team is expected to make a difficult and
serious decision. We believe that our new scoring system
may prove helpful to make a decision in all directions, be it
a therapy escalation employing an ECMO or a VAD, be it
maintaining the actual therapy with an IABP or be it the
cessation of the therapy in the most complex cases.
During the study period, an ECMO or a VAD were used
very restrictively in patients having postcardiotomy LOS in
our institute and it is the clear limitation of this study.
Therefore, two previous German studies [4, 5] may be
better for identifying patients requiring an ECMO or a
VAD due to postcardiotomy LOS. Nevertheless, the focus
of the present study was rather on identifying patients in
whom the therapy cessation may be justified. For example,
therapy escalation from IABP to an ECMO or a VAD may
not be indicated in an 85 year old patients having very poor
Table 3 continued
Mortality Univariate analysis Multivariate analysis
p p OR 95 % CI
Ventilation time C6 days
Yes 67/145 (46.2 %) 0.0001 0.932 0.972 0.515 1.837
No 100/402 (24.9 %)
Max. CK C 3000 mg mL-1
Yes 50/111 (45.0 %) 0.0001 0.05 1.714 1.002 2.973
No 120/441 (27.2 %)
Fig. 1 30 day mortality according to the scoring system
Fig. 2 a Estimated cumulative survival curve for the entire patient
cohort. b Estimated survival curve stratified for score values
according to the scoring system
Fig. 3 ROC curve for the scoring system
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left ventricular function due to perioperative myocardial
infarction. In this meaning, the present study would be
worth despite of the clear study limitation.
In conclusion, patients needing an IABP-support due to
LOS after cardiac surgery still belong to a high risk cohort.
Prediction of 30-day mortality was possible with our
scoring system based on multivariate analysis, and patients
with score values of 4 or more had obviously worse early
and late survival. We believe that our new scoring system
may be helpful to meet a decision in all directions; therapy
escalation with an ECMO or a VAD, maintaining the
actual therapy with an IABP or therapy cessation.
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